---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-051047"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:25:10.999143+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval

## Summary
- Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.
- Operating expenses $287M (+31% YoY); loss from operations $143M vs. $59M loss in Q3 2022.
- Cash and short-term investments $2.2B; reaffirmed 2023 financial guidance.
- Eplontersen regulatory submissions accepted in EU and Canada; potential U.S. approval in Dec 2023.
- Olezarsen Phase 3 Balance study met endpoints: significant triglyceride lowering, reduced pancreatitis attacks; on track for early 2024 filings.

## SEC filing metadata
- accession: 0001140361-23-051047
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/0001140361-23-051047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/ef20013902_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-051047
- JSON: https://secwatch.observer/filing/0001140361-23-051047.json
- Plain text: https://secwatch.observer/filing/0001140361-23-051047.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC updated its the third quarter of 2023 guidance (reaffirmed).
  - Period: the third quarter of 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: today reported financial results for the third quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/0001140361-23-051047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.